In light of Omnicare’s dropped bid for PharMerica, the Federal Trade Commission has voted 4-0 to dismiss its complaint to block the deal.
In the complaint, the FTC asserted that the merger would allow Omnicare to raise the price of drugs for Medicare Part D because the number of skilled nursing facilities receiving services from Omnicare would “dramatically increas[e],” thereby also increasing Omnicare’s bargaining power to raise the price of drugs to Part D health plans.
Source: Bloomberg
Related content: Interview with Jon Leibowitz
Featured News
CMA Appoints Joel Bamford as Executive Director for Mergers
Nov 29, 2023 by
CPI
Alibaba Health’s $1.73 Billion Deal to Boost Online Health Store Services
Nov 28, 2023 by
CPI
Nvidia Faces Global Regulatory Scrutiny Amid Antitrust Investigations
Nov 28, 2023 by
CPI
Meta Plans Appeal Following Judge’s Ruling in Privacy Battle with FTC
Nov 28, 2023 by
CPI
Tiger Woods Voices Discontent Over PGA Tour’s Saudi Agreement
Nov 28, 2023 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Consent Decrees
Nov 15, 2023 by
CPI
Consent Decrees Under the Biden Administration
Nov 15, 2023 by
CPI
The FTC´s Prior Approval Mischief
Nov 15, 2023 by
CPI
Fix-It-First: A Seismic Shift in U.S. Antitrust Agency Approaches to Merger Remedies
Nov 15, 2023 by
CPI
“Shadow” Settlements and the Tunney Act
Nov 15, 2023 by
CPI